Peutz-Jeghers syndrome (PJS) is anautosomal dominant condition characterized by the association ofgastrointestinal polyposis and mucocutaneous pigmentation. Peutz-Jeghers-typehamartomatous polyps are most common in the small intestine (in order ofprevalence: in the jejenum, ileum, and duodenum) but can also occur in thestomach and large bowel. Gastrointestinal polyps can result in chronic bleedingand anemia and cause recurrent obstruction and intussusception requiringrepeated laparotomies and bowel resections. Variableexpressivity is common; some affected individuals in families with PJS may have only polyps or perioral pigmentation.
The age at onset for symptoms frompolyps is variable, with some individuals developing symptoms within the firstfew years of life. Significant interfamilialvariability is observed in the age at which polyps are firstobserved, suggesting that the natural history of polyps in a family may be apredictor of severity for offspring. In studies from MD Anderson Cancer Center,the median age at first GI symptoms was ten years, while the median age atfirst polypectomy was age 13 years. A report from Korea indicated a mean age of onsetfor GI symptoms of 12.5 years. In a review of 32 kindreds with PJS, laparotomyfor bowel obstruction was performed in 30% of individuals by age ten years andin 68% by age 18 years.
Mucocutaneous hyperpigmentationpresents in childhood as dark blue to dark brown macules around the mouth,eyes, and nostrils, in the perianal area, and on the buccal mucosa.Hyperpigmented macules on the fingers are common. The macules may fade inpuberty and adulthood. Individuals with Peutz-Jeghers syndrome are at increasedrisk for malignancies (colorectal, gastric, pancreatic, breast, and ovariancancers). Females are at risk for sex cord tumors with annular tubules (SCTAT),a benign neoplasm of the ovaries, and adenoma malignum of the cervix, a rareaggressive cancer. Males occasionally develop calcifying Sertoli cell tumors ofthe testes, which secrete estrogen and can lead to gynecomastia.
The diagnosis of Peutz-Jegherssyndrome is based on clinical findings. In individuals with a clinicaldiagnosis of PJS, molecular genetictesting of the STK11(LKB1) gene (19p13.3) reveals disease-causing mutations in approximately 100% ofindividuals who have a positive family history and approximately 90% of individuals who have no family history of PJS.
About 50% of probands have an affected parent and about 50% have no family history of PJS, but the proportion of cases caused by de novo gene mutations is unknown as the frequency of subtle signs of the disorder inparents has not been thoroughly evaluated and molecular genetic data areinsufficient. Parents of affected individuals with no known family history of PJS should be evaluated clinically, and with molecular genetictesting if a disease-causing STK11 mutation has been identified in the proband.The risk to the offspring of a proband with a positive family history is 50%. The risk to offspring of a proband with a negative family history is 50% if the proband tests positive for a pathogenic STK11 mutation.The risk to offspring of a proband with no family history of PJS who tests negative for an STK11 mutation remains unknown.
For patients with suspected PJS, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.
Click here for the GeneTests summary on this condition.
This test is indicated for:
- Confirmation of a clinical diagnosis of PJS
- Individuals at-risk for PJS due to family history
Clinical Sensitivity: Approximately 100% of individuals who have a positive family history and approximately 90% of individuals who have no family history of PJS. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient''''''''s biochemical phenotype.
Analytical Sensitivity: ~99%
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Orangene™ Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.
Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.
Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.
- Deletion/duplication analysis of the STK11 gene by CGH array is available for those individuals in whom sequence analysis is negative (VM).
- Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to individuals who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.